Pharma

Global Radiopharmaceuticals Market Opportunities and Forecast 2020-2027

  • DLR2134
  • 22 November, 2021
  • Pharma & Healthcare
  • Pages: 120
  • Global
Global Radiopharmaceuticals Market, By Compound (Fluorine-18 Derivatives, Technetium-99, Lutetium [Lu] 177, Gallium-68, Zirconium 89, 11C-choline,14C-urea, Others) By System (PET, SPECT) By Indication (Oncology, Neurology, Cardiology, Others) By End-user (Hospitals, Diagnostic Labs, Others), and opportunities and forecast 2020-2027

Radiopharmaceuticals Market Overview

The radiopharmaceuticals industry, a sub-branch of the pharmaceutical sector, has a distinct structure. Radiopharmaceuticals are radioisotopes that have been bonded to biological molecules and can target specific organs, tissues, or cells in the human body. These radioactive medications can be used for disease diagnosis and, in some cases, therapy. Radiopharmaceuticals are biologically active compounds that have been tagged with radionuclides to provide a useful source of ionizing radiation for diagnostic imaging and therapy. The global Radiopharmaceuticals market is projected to rise at a considerable rate in the forthcoming years.
 
Currently, diagnostic laboratories and hospitals use radiopharmaceuticals compounds to superimpose nuclear medicine images with computed tomography (CT) or magnetic resonance imaging (MRI) to provide exceptional perspectives. The image is created by using an isotope compound as a tracer. Image fusion or co-registration is the term for this. This is one of the factors that boost the demand for radiopharmaceuticals compounds.
 
In recent years, there has been an upsurge in funding towards the development of novel radioisotope-based theranostic agents. After decades of neglect by the pharmaceutical industry, radiopharmaceuticals are now generating large cancer deals all over the world. This could lead to an increase in 'theranostics,' or cancer medications that can be used as both therapies and diagnostics. All these aforementioned factors are majorly contributed to the growth of the global Radiopharmaceuticals market.

Report Metric Details
Market size available for years 2019–2027
Base year considered 2019
Forecast period 2020–2027
Forecast unit Value (USD Million)
Segments covered Compound, System, Indication, End-user, and Region
Regions covered North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA)
Companies covered Siemens Healthineers, GE Healthcare, Advanced Accelerator Applications (a Novartis AG Company), Jubilant Pharma Limited, Bayer AG, ITM Isotopen Technologien München AG, Telix Pharmaceuticals, Lantheus Holdings, Inc., Eli Lilly and Company, Nihon Medi-Physics, Avanos Medical, Inc.


Covid-19 Impact on Radiopharmaceuticals Market
 
In addition, the current Radiopharmaceuticals Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Radiopharmaceuticals Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.

The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
 
Radiopharmaceuticals Market Segment Overview



According to the System, PET is one of the largest segments in the global Radiopharmaceuticals market. As the global prevalence of cancer rises, so does the demand for PET imaging to provide appropriate treatment. The PET/PET-CT test aids in the diagnosis of cancer and provides additional information, such as whether a tumor is benign or malignant and how well it responds to treatment. This imaging modality is particularly sensitive in detecting malignant tissues and has a high specificity, which is the primary reason for fewer ambiguous scans and improved diagnostic outcomes. The need for radiopharmaceuticals compounds is propelled by this.
 
Radiopharmaceuticals Market, By Compound
·       Fluorine-18 Derivatives
·       Technetium-99
·       Lutetium [Lu] 177
·       Gallium-68
·       Zirconium 89
·       11C-choline
·       14C-urea
·       Others
 
Radiopharmaceuticals Market, By System
·       PET 
·       SPECT
 
Radiopharmaceuticals Market, By Indication
·       Oncology
·       Neurology
·       Cardiology
·       Others
 
Radiopharmaceuticals Market, By End-user
·       Hospitals
·       Diagnostic Labs
·       Others
 
Radiopharmaceuticals Market Regional Overview

Geographically, North America holds a dominant position in the market and going forward too will likely retain its stronghold. In 2020, the United States accounted for the majority of the radiopharmaceuticals market in North America. During the forecast period, the country is expected to maintain its market share. The United States' dominance in the radiopharmaceuticals market in the region can be due to its well-established healthcare infrastructure and early adoption of modern imaging equipment. During the forecast period, Asia Pacific is expected to acquire market share. Product launches, acquisitions, distribution agreements, collaborations, and geographic expansion by competitors are likely to boost the radiopharmaceuticals market in the region, particularly in China and India.

Radiopharmaceuticals Market, By Geography
 
·       North America (US & Canada)
·       Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
·       Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
·       LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
 
 Radiopharmaceuticals Market, Key Players

·       Siemens Healthineers
·       GE Healthcare
·       Advanced Accelerator Applications (a Novartis AG Company)
·       Jubilant Pharma Limited
·       Bayer AG
·       ITM Isotopen Technologien München AG
·       Telix Pharmaceuticals
·       Lantheus Holdings, Inc.
·       Eli Lilly and Company
·       Nihon Medi-Physics
·       Avanos Medical, Inc.
 

Frequently Asked Questions (FAQ) :

Q1. Which Segments are covered in the Radiopharmaceuticals Market report?

A. Compound, System, Indication, End-user, and Region these segments are covered in the Radiopharmaceuticals market report.

Q2. Which are the parts of the Indication segment in the Radiopharmaceuticals market?

A. Oncology, Neurology, Cardiology, Others are parts of the end-use industry segment in the Radiopharmaceuticals market

Q3. Which segment is projected to hold the largest share in the Radiopharmaceuticals Market?

A. The PET segment is projected to hold the largest share in the Radiopharmaceuticals Market

Q4. Which region holds the largest share in the Radiopharmaceuticals market?

A. North America held the largest share in the global Radiopharmaceuticals market

Q5. Which are the prominent players in the Radiopharmaceuticals Market?

A. Siemens Healthineers, GE Healthcare, Advanced Accelerator Applications (a Novartis AG Company), Jubilant Pharma Limited, Bayer AG, ITM Isotopen Technologien München AG, Telix Pharmaceuticals, Lantheus Holdings, Inc., Eli Lilly and Company, Nihon Medi-Physics, Avanos Medical, Inc. are some key players in the Radiopharmaceuticals Market.
Radiopharmaceuticals Market Study Global Market Analysis, Insights and Forecast, 2020-2027

    1. Introduction

    • 1.1. Research Scope
    • 1.2. Market Segmentation
    • 1.3. Research Methodology
    • 1.4. Definitions and Assumptions

    2. Executive Summary

      3. Market Dynamics

      • 3.1. Market Drivers
      • 3.2. Market Restraints
      • 3.3. Market Opportunities

      4. Key Insights

      • 4.1. Key Emerging Trends – For Major Countries
      • 4.2. Latest Technological Advancement
      • 4.3. Regulatory Landscape
      • 4.4. Industry SWOT Analysis
      • 4.5. Porters Five Forces Analysis

      5. Global Radiopharmaceuticals Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 5.1. Key Findings / Summary
      • 5.2. Market Analysis, Insights and Forecast – By Compound
        • 5.2.1. Fluorine-18 Derivatives
        • 5.2.2. Technetium-99
        • 5.2.3. Lutetium [Lu] 177
        • 5.2.4. Gallium-68
        • 5.2.5. Zirconium 89
        • 5.2.6. 11C-choline
        • 5.2.7. 14C-urea
        • 5.2.8. Others
      • 5.3. Market Analysis, Insights and Forecast – By System
        • 5.3.1. PET
        • 5.3.2. SPECT
      • 5.4. Market Analysis, Insights and Forecast – By Indication
        • 5.4.1. Oncology
        • 5.4.2. Neurology
        • 5.4.3. Cardiology
        • 5.4.4. Others
      • 5.5. Market Analysis, Insights and Forecast – By End-user
        • 5.5.1. Hospitals
        • 5.5.2. Diagnostic Labs
        • 5.5.3. Others
      • 5.6. Market Analysis, Insights and Forecast – By Region
        • 5.6.1. North America
        • 5.6.2. Europe
        • 5.6.3. Asia Pacific
        • 5.6.4. Latin America, Middle East and Africa

      6. North America Radiopharmaceuticals Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 6.1. Key Findings / Summary
      • 6.2. Market Analysis, Insights and Forecast – By Compound
        • 6.2.1. Fluorine-18 Derivatives
        • 6.2.2. Technetium-99
        • 6.2.3. Lutetium [Lu] 177
        • 6.2.4. Gallium-68
        • 6.2.5. Zirconium 89
        • 6.2.6. 11C-choline
        • 6.2.7. 14C-urea
        • 6.2.8. Others
      • 6.3. Market Analysis, Insights and Forecast – By System
        • 6.3.1. PET
        • 6.3.2. SPECT
      • 6.4. Market Analysis, Insights and Forecast – By Indication
        • 6.4.1. Oncology
        • 6.4.2. Neurology
        • 6.4.3. Cardiology
        • 6.4.4. Others
      • 6.5. Market Analysis, Insights and Forecast – By End-user
        • 6.5.1. Hospitals
        • 6.5.2. Diagnostic Labs
        • 6.5.3. Others
      • 6.6. Market Analysis, Insights and Forecast – By Country
        • 6.6.1. U.S.
        • 6.6.2. Canada

      7. Europe Radiopharmaceuticals Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 7.1. Key Findings / Summary
      • 7.2. Market Analysis, Insights and Forecast – By Compound
        • 7.2.1. Fluorine-18 Derivatives
        • 7.2.2. Technetium-99
        • 7.2.3. Lutetium [Lu] 177
        • 7.2.4. Gallium-68
        • 7.2.5. Zirconium 89
        • 7.2.6. 11C-choline
        • 7.2.7. 14C-urea
        • 7.2.8. Others
      • 7.3. Market Analysis, Insights and Forecast – By System
        • 7.3.1. PET
        • 7.3.2. SPECT
      • 7.4. Market Analysis, Insights and Forecast – By Indication
        • 7.4.1. Oncology
        • 7.4.2. Neurology
        • 7.4.3. Cardiology
        • 7.4.4. Others
      • 7.5. Market Analysis, Insights and Forecast – By End-user
        • 7.5.1. Hospitals
        • 7.5.2. Diagnostic Labs
        • 7.5.3. Others
      • 7.6. Market Analysis, Insights and Forecast – By Country
        • 7.6.1. UK
        • 7.6.2. Germany
        • 7.6.3. France
        • 7.6.4. Italy
        • 7.6.5. Spain
        • 7.6.6. Russia
        • 7.6.7. Rest of Europe

      8. Asia Pacific Radiopharmaceuticals Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 8.1. Key Findings / Summary
      • 8.2. Market Analysis, Insights and Forecast – By Compound
        • 8.2.1. Fluorine-18 Derivatives
        • 8.2.2. Technetium-99
        • 8.2.3. Lutetium [Lu] 177
        • 8.2.4. Gallium-68
        • 8.2.5. Zirconium 89
        • 8.2.6. 11C-choline
        • 8.2.7. 14C-urea
        • 8.2.8. Others
      • 8.3. Market Analysis, Insights and Forecast – By System
        • 8.3.1. PET
        • 8.3.2. SPECT
      • 8.4. Market Analysis, Insights and Forecast – By Indication
        • 8.4.1. Oncology
        • 8.4.2. Neurology
        • 8.4.3. Cardiology
        • 8.4.4. Others
      • 8.5. Market Analysis, Insights and Forecast – By End-user
        • 8.5.1. Hospitals
        • 8.5.2. Diagnostic Labs
        • 8.5.3. Others
      • 8.6. Market Analysis, Insights and Forecast – By Country
        • 8.6.1. China
        • 8.6.2. India
        • 8.6.3. Japan
        • 8.6.4. Australia
        • 8.6.5. South East Asia
        • 8.6.6. Rest of Asia Pacific

      9. Latin America, Middle East and Africa Radiopharmaceuticals Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 9.1. Key Findings / Summary
      • 9.2. Market Analysis, Insights and Forecast – By Compound
        • 9.2.1. Fluorine-18 Derivatives
        • 9.2.2. Technetium-99
        • 9.2.3. Lutetium [Lu] 177
        • 9.2.4. Gallium-68
        • 9.2.5. Zirconium 89
        • 9.2.6. 11C-choline
        • 9.2.7. 14C-urea
        • 9.2.8. Others
      • 9.3. Market Analysis, Insights and Forecast – By System
        • 9.3.1. PET
        • 9.3.2. SPECT
      • 9.4. Market Analysis, Insights and Forecast – By Indication
        • 9.4.1. Oncology
        • 9.4.2. Neurology
        • 9.4.3. Cardiology
        • 9.4.4. Others
      • 9.5. Market Analysis, Insights and Forecast – By End-user
        • 9.5.1. Hospitals
        • 9.5.2. Diagnostic Labs
        • 9.5.3. Others
      • 9.6. Market Analysis, Insights and Forecast – By Country
        • 9.6.1. Brazil
        • 9.6.2. Saudi Arabia
        • 9.6.3. UAE
        • 9.6.4. Rest of LAMEA

      10. Competitive Analysis

      • 10.1. Company Market Share Analysis, 2018
      • 10.2. Key Industry Developments
      • 10.3. Company Profile
      • 10.4. Siemens Healthineers
        • 10.4.1. Business Overview
        • 10.4.2. Segment 1 & Service Offering
        • 10.4.3. Overall Revenue
        • 10.4.4. Geographic Presence
        • 10.4.5. Recent Development
      *Similar details will be provided for the following companies
      • 10.5. GE Healthcare
      • 10.6. Advanced Accelerator Applications (a Novartis AG Company)
      • 10.7. Jubilant Pharma Limited
      • 10.8. Bayer AG
      • 10.9. ITM Isotopen Technologien München AG
      • 10.10. Telix Pharmaceuticals
      • 10.11. Lantheus Holdings, Inc.
      • 10.12. Eli Lilly and Company
      • 10.13. Nihon Medi-Physics
      List of Figures

      Figure 1: Global Radiopharmaceuticals Market Revenue Breakdown (USD Billion, %) by Region, 2019 & 2027
      Figure 2: Global Radiopharmaceuticals Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 3: Global Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 4: Global Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 5: Global Radiopharmaceuticals Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 6: Global Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 7: Global Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 8: Global Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 9: Global Radiopharmaceuticals Market Forecast (USD Billion), by Others, 2016-2027
      Figure 10: Global Radiopharmaceuticals Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 11: Global Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 12: Global Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 13: Global Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 14: Global Radiopharmaceuticals Market Forecast (USD Billion), by Others, 2016-2027
      Figure 15: Global Radiopharmaceuticals Market Value (USD Billion), by Region, 2019 & 2027
      Figure 16: North America Radiopharmaceuticals Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 17: North America Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 18: North America Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 19: North America Radiopharmaceuticals Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 20: North America Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 21: North America Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 22: North America Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 23: North America Radiopharmaceuticals Market Forecast (USD Billion), by Others, 2016-2027
      Figure 24: North America Radiopharmaceuticals Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 25: North America Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 26: North America Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 27: North America Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 28: North America Radiopharmaceuticals Market Forecast (USD Billion), by Others, 2016-2027
      Figure 29: North America Radiopharmaceuticals Market Forecast (USD Billion), by U.S., 2016-2027
      Figure 30: North America Radiopharmaceuticals Market Forecast (USD Billion), by Canada, 2016-2027
      Figure 31: Latin America Radiopharmaceuticals Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 32: Latin America Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 33: Latin America Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 34: Latin America Radiopharmaceuticals Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 35: Latin America Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 36: Latin America Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 37: Latin America Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 38: Latin America Radiopharmaceuticals Market Forecast (USD Billion), by Others, 2016-2027
      Figure 39: Latin America Radiopharmaceuticals Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 40: Latin America Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 41: Latin America Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 42: Latin America Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 43: Latin America Radiopharmaceuticals Market Forecast (USD Billion), by Others, 2016-2027
      Figure 44: Latin America Radiopharmaceuticals Market Forecast (USD Billion), by Brazil, 2016-2027
      Figure 45: Latin America Radiopharmaceuticals Market Forecast (USD Billion), by Mexico, 2016-2027
      Figure 46: Latin America Radiopharmaceuticals Market Forecast (USD Billion), by Rest of Latin America, 2016-2027
      Figure 47: Europe Radiopharmaceuticals Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 48: Europe Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 49: Europe Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 50: Europe Radiopharmaceuticals Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 51: Europe Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 52: Europe Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 53: Europe Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 54: Europe Radiopharmaceuticals Market Forecast (USD Billion), by Others, 2016-2027
      Figure 55: Europe Radiopharmaceuticals Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 56: Europe Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 57: Europe Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 58: Europe Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 59: Europe Radiopharmaceuticals Market Forecast (USD Billion), by Others, 2016-2027
      Figure 60: Europe Radiopharmaceuticals Market Forecast (USD Billion), by U.K., 2016-2027
      Figure 61: Europe Radiopharmaceuticals Market Forecast (USD Billion), by Germany, 2016-2027
      Figure 62: Europe Radiopharmaceuticals Market Forecast (USD Billion), by France, 2016-2027
      Figure 63: Europe Radiopharmaceuticals Market Forecast (USD Billion), by Italy, 2016-2027
      Figure 64: Europe Radiopharmaceuticals Market Forecast (USD Billion), by Spain, 2016-2027
      Figure 65: Europe Radiopharmaceuticals Market Forecast (USD Billion), by Russia, 2016-2027
      Figure 66: Europe Radiopharmaceuticals Market Forecast (USD Billion), by Rest of Europe, 2016-2027
      Figure 67: Asia Pacific Radiopharmaceuticals Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 68: Asia Pacific Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 69: Asia Pacific Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 70: Asia Pacific Radiopharmaceuticals Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 71: Asia Pacific Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 72: Asia Pacific Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 73: Asia Pacific Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 74: Asia Pacific Radiopharmaceuticals Market Forecast (USD Billion), by Others, 2016-2027
      Figure 75: Asia Pacific Radiopharmaceuticals Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 76: Asia Pacific Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 77: Asia Pacific Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 78: Asia Pacific Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 79: Asia Pacific Radiopharmaceuticals Market Forecast (USD Billion), by Others, 2016-2027
      Figure 80: Asia Pacific Radiopharmaceuticals Market Forecast (USD Billion), by China, 2016-2027
      Figure 81: Asia Pacific Radiopharmaceuticals Market Forecast (USD Billion), by India, 2016-2027
      Figure 82: Asia Pacific Radiopharmaceuticals Market Forecast (USD Billion), by Japan, 2016-2027
      Figure 83: Asia Pacific Radiopharmaceuticals Market Forecast (USD Billion), by Australia, 2016-2027
      Figure 84: Asia Pacific Radiopharmaceuticals Market Forecast (USD Billion), by Southeast Asia, 2016-2027
      Figure 85: Asia Pacific Radiopharmaceuticals Market Forecast (USD Billion), by Rest of Asia Pacific, 2016-2027
      Figure 86: Middle East & Africa Radiopharmaceuticals Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 87: Middle East & Africa Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 88: Middle East & Africa Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 89: Middle East & Africa Radiopharmaceuticals Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 90: Middle East & Africa Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 91: Middle East & Africa Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 92: Middle East & Africa Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 93: Middle East & Africa Radiopharmaceuticals Market Forecast (USD Billion), by Others, 2016-2027
      Figure 94: Middle East & Africa Radiopharmaceuticals Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 95: Middle East & Africa Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 96: Middle East & Africa Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 97: Middle East & Africa Radiopharmaceuticals Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 98: Middle East & Africa Radiopharmaceuticals Market Forecast (USD Billion), by Others, 2016-2027
      Figure 99: Middle East & Africa Radiopharmaceuticals Market Forecast (USD Billion), by GCC, 2016-2027
      Figure 100: Middle East & Africa Radiopharmaceuticals Market Forecast (USD Billion), by South Africa, 2016-2027
      Figure 101: Middle East & Africa Radiopharmaceuticals Market Forecast (USD Billion), by Rest of Middle East & Africa, 2016-2027 
      List of Tables
      Table 1: Global Radiopharmaceuticals Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 2: Global Radiopharmaceuticals Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 3: Global Radiopharmaceuticals Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 4: Global Radiopharmaceuticals Market Revenue (USD Billion) Forecast, by Region, 2016-2027
      Table 5: North America Radiopharmaceuticals Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 6: North America Radiopharmaceuticals Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 7: North America Radiopharmaceuticals Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 8: North America Radiopharmaceuticals Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 9: Europe Radiopharmaceuticals Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 10: Europe Radiopharmaceuticals Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 11: Europe Radiopharmaceuticals Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 12: Europe Radiopharmaceuticals Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 13: Latin America Radiopharmaceuticals Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 14: Latin America Radiopharmaceuticals Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 15: Latin America Radiopharmaceuticals Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 16: Latin America Radiopharmaceuticals Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 17: Asia Pacific Radiopharmaceuticals Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 18: Asia Pacific Radiopharmaceuticals Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 19: Asia Pacific Radiopharmaceuticals Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 20: Asia Pacific Radiopharmaceuticals Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 21: Middle East & Africa Radiopharmaceuticals Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 22: Middle East & Africa Radiopharmaceuticals Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 23: Middle East & Africa Radiopharmaceuticals Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 24: Middle East & Africa Radiopharmaceuticals Market Revenue (USD Billion) Forecast, by Country, 2016-2027

      Report You Might be Interested

      Choose License Type

      • USD
      • GBP
      • EURO
      • INR
      Credit card Logo

      Happy To Assist You

      Have a Question? email us at

      info@datalibraryresearch.com

      Or Call Us On

      US +1 360 851 1343

      IND +91 880 579 4934